P00519 (ABL1_HUMAN) Homo sapiens (Human)

Tyrosine-protein kinase ABL1 UniProtKBInterProSTRINGInteractive Modelling

1130 aa; Sequence (Fasta) ; (Isoform 2)

Available Structures

81 Experimental Structures

DescriptionPDB IDOligo-stateRangeLigands
Crystal structure of monobody SH13/ABL1 SH2 domain complex
3uyo
 Heteromer
115-228
1×SO4;
Assess
CRYSTAL STRUCTURE OF MONOBODY AS25/ABL1 SH2 DOMAIN COMPLEX, CRYSTAL A
5dc4
 Heteromer
P02751; 		121-220
1×GOL;
Assess
CRYSTAL STRUCTURE OF MONOBODY AS25/ABL1 SH2 DOMAIN COMPLEX, CRYSTAL B
5dc9
 Heteromer
P02751; 		121-220
5×GOL; 2×IMD;
Assess
Crystal Structure of Monobody HA4/Abl1 SH2 Domain Complex
3k2m
 Heteromer
121-220
1×PO4;
Assess
Crystal structure of monobody 7c12/abl1 sh2 domain complex
3t04
 Heteromer
122-219
4×GOL; 1×SO4;
Assess
CRYSTAL STRUCTURE OF MONOBODY GG3/ABL1 SH2 DOMAIN COMPLEX
5dc0
 Heteromer
P02751; 		122-219
Assess
Crystal structure of the Abl-SH3 domain complexed with the high affinity peptide P0
4j9f
 Heteromer
Q9Y3L3; 		60-120
Assess
Ternary complex of an Crk SH2 domain, Crk-derived phophopeptide, and Abl SH3 domain by NMR spectros…
1ju5
 Heteromer
P46108; Q64010; 		62-121
Assess
Crystal structure of the N114A mutant of the Abl-SH3 domain complexed with the high affinity peptid…
4j9d
 Heteromer
Q9Y3L3; 		65-120
Assess
C-abl Kinase domain with the activator(cmpd6), 2-cyano-N-(4-(3,4-dichlorophenyl)thiazol-2-yl)acetam…
6npe
homo-2-mer232-511
4×SO4; 2×STI; 2×KWD; 1×2PE;
Assess
C-abl Kinase domain with the activator(cmpd29), N-(1-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-3-…
6npu
homo-2-mer232-510
2×STI; 2×KWV; 1×SO4; 2×GOL; 1×2PE;
Assess
The crystal structure of human abl1 kinase domain in complex with ABL1-A11
7w7x
homo-2-mer232-500
2×8DW;
Assess
The crystal structure of human abl1 kinase domain in complex with ABL2-A5
7w7y
homo-2-mer232-500
2×8IW;
Assess
Crystal structure of the N114Q mutant of ABL-SH3 domain complexed with a designed high-affinity pep…
3eg1
homo-2-mer64-121
2×SO4;
Assess
Organization of the SH3-SH2 Unit in Active and Inactive Forms of the c-Abl Tyrosine Kinase
2fo0
monomer46-511
1×MYR; 1×P16; 2×GOL;
Assess
Structural basis for the auto-inhibition of c-Abl tyrosine kinase
1opl
monomer62-512
1×MYR; 1×P16;
Assess
ABL1 kinase (T334I_D382N) in complex with asciminib and nilotinib
5mo4
monomer64-512
1×NIL; 1×AY7;
Assess
Abl kinase in complex with SKI and asciminib
8ssn
monomer64-507
1×AY7; 1×SKI; 1×CL; 2×SO4; 3×DMS;
Assess
Structure of the Kinase Domain of an Imatinib-Resistant Abl Mutant in Complex with the Aurora Kinas…
2f4j
monomer227-513
1×VX6;
Assess
Abl 1b isoform active state
6xr6
monomer229-515
Assess
Abl isoform 1b inactive1 state
6xr7
monomer229-515
Assess
Abl 1b isoform inactive2 state
6xrg
monomer229-515
Assess
A Src-like Inactive Conformation in the Abl Tyrosine Kinase Domain
2g2f
monomer232-506
1×112;
Assess
Crystal structure of the c-Abl kinase domain in complex with INNO-406
2e2b
monomer229-502
1×406;
Assess
A Src-like Inactive Conformation in the Abl Tyrosine Kinase Domain
2g2i
monomer229-502
1×ADP;
Assess
Crystal structure of an SH2-kinase domain construct of c-Abl tyrosine kinase
4xey
monomer231-503
1×1N1;
Assess
A Src-like Inactive Conformation in the Abl Tyrosine Kinase Domain
2g2h
monomer233-504
1×P16;
Assess
X-ray Crystal Structure of Dasatinib (BMS-354825) Bound to Activated ABL Kinase Domain
2gqg
monomer229-500
1×1N1;
Assess
Crystal structure of ABL1 in complex with CHMFL-074
5hu9
monomer229-499
2×66K; 12×EDO; 1×CL;
Assess
A Src-like Inactive Conformation in the Abl Tyrosine Kinase Domain
2g1t
monomer232-502
1×MG; 1×112;
Assess
The crystal structure of human abl1 T315I gatekeeper mutant kinase domain in complex with axitinib
4twp
monomer233-503
1×AXI; 2×NI; 2×NA;
Assess
Crystal structure of the T315I Abl mutant in complex with the inhibitor PHA-739358
2v7a
monomer233-503
1×627; 1×MG;
Assess
The crystal structure of human abl1 kinase domain in complex with DCC-2036
3qri
monomer229-498
2×NA; 1×919;
Assess
Crystal Structure of Inactive Conformation Abl Kinase Catalytic Domain Complexed with Type II Inhib…
2hiw
monomer230-499
1×7MP;
Assess
Structural and spectroscopic analysis of the kinase inhibitor bosutinib binding to the Abl tyrosine…
3ue4
monomer233-502
1×DB8;
Assess
Predicting the Conformational Variability of Abl Tyrosine Kinase Using Molecular Dynamics Simulatio…
6bl8
monomer233-502
1×PVB; 1×SO4;
Assess
Discovery and Characterization of a Cell-Permeable, Small-molecule c-Abl Kinase Activator that Bind…
3pyy
monomer232-500
2×SO4; 1×STI; 1×3YY;
Assess
C-abl Kinase domain with the activator(cmpd51), N-(1-(3,4-dichlorophenyl)-4-(2-hydroxyethyl)-4,5-di…
6npv
monomer232-500
1×SO4; 1×STI; 1×KWP;
Assess
The crystal structure of human abl1 kinase domain in complex with abl1-A-EBA
8h7h
monomer232-500
1×QH9;
Assess
VX-680/MK-0457 binds to human ABL1 also in inactive DFG conformations.
4zog
monomer233-501
1×VX6; 3×MXE;
Assess
The crystal structure of human abl1 kinase domain in complex with abl1-B-EBA
8h7f
monomer232-500
1×QEW;
Assess
Strategic design of catalytic lysine-targeting reversible covalent BCR-ABL Inhibitors
7cc2
monomer233-501
1×FVC;
Assess
C-Helix-Out Binding of Dasatinib Analog to c-Abl Kinase
4yc8
monomer233-501
1×4B7; 1×EDO; 1×MES;
Assess
Abl kinase domain in complex with PD180970
2hzi
monomer233-500
1×JIN;
Assess
Human ABL kinase in complex with nilotinib
3cs9
monomer233-500
1×NIL;
Assess
Strategic design of catalytic lysine-targeting reversible covalent BCR-ABL Inhibitors
7dt2
monomer233-500
1×HJ9;
Assess
The crystal structure of human abl1 kinase domain in complex with DP-987
3qrk
monomer229-496
1×9DP;
Assess
Abl kinase domain unligated and in complex with tetrahydrostaurosporine
2hz4
monomer234-500
1×4ST;
Assess
Crystal structure of the Abl 1b Kinase domain in complex with Dasatinib and Imatinib
7n9g
monomer233-498
1×STI; 1×1N1; 1×PO4;
Assess
Abl kinase domain in complex with NVP-AEG082
2hz0
monomer233-497
1×GIN;
Assess
Human Abl kinase domain in complex with imatinib (STI571, Glivec)
2hyy
monomer235-498
1×STI;
Assess
The crystal structure of human abl1 kinase domain T315I mutant in complex with DCC-2036
3qrj
monomer234-496
1×919;
Assess
The crystal structure of human abl1 wild type kinase domain in complex with axitinib
4wa9
monomer246-508
1×AXI;
Assess
Abl 1b Regulatory Module 'inhibiting state
6amv
monomer6-236
Assess
Abl1b Regulatory Module 'Activating' conformation
6amw
monomer6-236
Assess
SH3-SH2 DOMAIN FRAGMENT OF HUMAN BCR-ABL TYROSINE KINASE
2abl
monomer57-218
Assess
Solution structure of the F-actin binding domain of Bcr-Abl/c-Abl
1zzp
monomer1024-1130
Assess
THREE-DIMENSIONAL SOLUTION STRUCTURE OF THE SRC HOMOLOGY 2 DOMAIN OF C-ABL
1ab2
monomer120-220
Assess
Crystal structure of the N114A mutant of ABL-SH3 domain
3eg3
monomer60-121
1×GOL;
Assess
Crystal structure of the N114A Abl-SH3 domain mutant at pH4
4jjd
monomer60-121
1×PEG; 2×NA;
Assess
Crystal structure of the N114Q mutant of ABL-SH3 domain
3eg2
monomer60-121
1×GOL;
Assess
Crystal structure of the Abl-SH3 domain at pH 7.5
5oaz
monomer62-120
1×PEG;
Assess
Crystal structure of the ABL-SH3 domain complexed with the designed high-affinity peptide ligand P7…
4j9h
monomer62-120
Assess
Crystal structure of the Abl SH3 domain V73E-A74S-S75R-G76T-D77E-G92N-Y93N-N94T-H95E mutant in pres…
7pvs
monomer63-120
1×PGE; 1×NA; 3×SO4;
Assess
Crystal structure of the Abl-SH3 domain H59Q-N96T mutant complexed with the designed high-affinity …
4j9c
monomer63-120
1×PGE; 1×PEG;
Assess
Crystal structure of the Abl SH3 domain V73E-A74S-S75R-G76T-D77E-G92N-Y93N-N94T-H95E mutant in the …
7pvq
monomer63-120
Assess
Crystal structure of the Abl-SH3 domain at pH5
4jjc
monomer64-121
1×PEG;
Assess
Crystal structure of the Abl SH3 domain V73E-A74S-S75R-G76T-D77E-G92N-Y93N-N94T-H95E mutant in the …
7pvr
monomer63-120
Assess
CRYSTAL STRUCTURE OF THE ABL-SH3 DOMAIN COMPLEXED WITH A DESIGNED HIGH-AFFINITY PEPTIDE LIGAND: IMP…
1bbz
monomer64-121
1×SO4;
Assess
Crystal structure of the Abl-SH3 domain H59Q-N96T mutant
4j9b
monomer63-120
2×PEG;
Assess
Crystal structure of the N114A mutant of ABL-SH3 domain complexed with a designed high-affinity pep…
2o88
monomer64-121
1×SO4;
Assess
Crystal structure of the ABL-SH3 domain complexed with the designed high-affinity peptide ligand P7…
4j9g
monomer63-120
Assess
Crystal structure of the Abl SH3 domain V73E-A74S-S75R-G76T-D77E mutant
7pw2
monomer63-119
Assess
Crystal structure of the Abl-SH3 domain at pH3
4jjb
monomer64-120
2×PEG; 1×SO4;
Assess
Crystal structure of the Abl SH3 domain G92N-Y93N-N94T-H95E mutant
7pvv
monomer64-120
1×PEG; 1×PGE;
Assess
Crystal structure of the N114A mutant of ABL-SH3 domain
3egu
monomer63-119
1×SO4; 1×GOL;
Assess
THE SOLUTION NMR STRUCTURE OF ABL SH3 AND ITS RELATIONSHIP TO SH2 IN THE SH(32) CONSTRUCT, 20 STRUC…
1awo
monomer64-120
Assess
Crystal structure of the N114A mutant of the Abl-SH3 domain complexed with the high affinity peptid…
4j9e
monomer65-120
Assess
Abl1 SH3 pTyr89/134
5np2
monomer64-119
Assess
Crystal structure of the ABL-SH3 domain complexed with the designed high-affinity peptide ligand P17
4j9i
monomer65-120
Assess
Crystal structure of the N114T mutant of ABL-SH3 domain
3eg0
monomer64-119
1×GOL;
Assess

4 SWISS-MODEL models

TemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
1opl.1.Amonomer0.8162-512
1×MYR; 1×P16;99.39
Assess
1opl.2.Amonomer0.78121-499
1×P16;99.39
Assess
1zzp.1.Amonomer0.771024-1130
99.19
Assess
1y57.1.Amonomer0.6964-500
43.06
Assess

4 SWISS-MODEL models built on isoform sequence

TemplateIsoformOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
Isoform 21opl.1.Amonomer0.8181-531
1×MYR; 1×P16;99.44
Assess
Isoform 21opl.2.Amonomer0.78140-518
1×P16;99.44
Assess
Isoform 21zzp.1.Amonomer0.771043-1149
99.19
Assess
Isoform 21y57.1.Amonomer0.6983-519
43.06
Assess